F-1/A: Innocan Pharma Files F-1/A for Nasdaq IPO, Funds CBD Drug Dev

Innocan Pharma Corporation filed an F-1/A registration statement for an initial public offering of 1,088,157 units on Nasdaq to fund its LPT-CBD chronic pain management drug development and expand its consumer wellness segment.

Summary

• Innocan Pharma Corporation is a pharmaceutical tech company with two segments: Pharmaceuticals (LPT-CBD drug delivery for human and animal health) and Consumer Wellness (self-care and beauty products).
• The company is pursuing an Initial Public Offering (IPO) of 1,088,157 units, each consisting of one common share and one warrant, with an estimated initial public offering price of $13.962 per unit.
• Common shares and warrants are expected to be listed on the Nasdaq Capital Market under symbols INNP and INNPW, respectively.
• Net proceeds from the offering, estimated at $12.98 million (or $14.9 million if over-allotment option is fully exercised), will primarily fund LPT-CBD research and development for human ($6.5 million) and veterinary ($2.5 million) applications, and marketing ($1 million).
• The LPT-CBD platform is in late pre-clinical development, with a pre-IND meeting successfully held with the FDA, structuring the path towards an IND submission.
• The company plans to submit an IND application for its initial Phase 1a study approximately one year after LPT-CBD scale-up activities commence (expected 3 months post-IPO).
• Innocan has a history of net losses, with an accumulated deficit of $36,080,000 as of June 30, 2025, and its financial statements contain a going concern explanatory paragraph.
• Revenues for the six months ended June 30, 2025, were $14,802,000, a decrease from $15,412,000 in the same period of 2024, attributed to challenging market conditions and global trade tariffs.
• Net loss for the six months ended June 30, 2025, was $544,000, an increase from $498,000 in the same period of 2024.
• The company's patent portfolio includes 31 published patents granted and pending across eight families, with one patent granted in India for liposomal cannabinoids and uses thereof.

Sentiment

Score: 4

Explanation: The company is at a critical pre-clinical stage for its primary pharmaceutical asset, LPT-CBD, with significant future funding needs and a going concern warning. While the Nasdaq IPO and positive pre-clinical data are encouraging, the increased net loss and decreased revenue in the most recent interim period, coupled with the inherent risks of drug development and geopolitical instability in Israel, indicate a high-risk investment profile. The potential for a streamlined regulatory pathway is a positive, but not guaranteed.

Positives

• The company is pursuing an IPO on the Nasdaq Capital Market, which could provide significant capital and increased visibility.
• LPT-CBD injectable platform shows promise in pre-clinical research for human and animal chronic pain management, offering a non-opioid alternative.
• A robust intellectual property portfolio with 31 published patents (granted and pending) protects core technology and proprietary approaches.
• Successful pre-IND meeting with the FDA has structured the development plan for LPT-CBD towards IND submission, utilizing the streamlined 505(b)(2) pathway.
• The FDA granted a sponsor fee waiver and INAD number for LPT-CBD in veterinary applications, facilitating development.
• The Consumer Wellness segment, particularly B.I. Sky, demonstrated strong organic growth in 2024, with revenues increasing by $11.09 million (70.3%) due to online sales.
• Efficacy testing for CBD wellness products shows positive results in pain relief (83% immediate improvement), diabetic foot relief (97% hydration increase), hair growth (22.5% increase in length), anti-wrinkle (up to 28.8% reduction), and anti-puffiness (52.18% reduction).
• The global pain management market is projected to reach $109 billion by 2032 (4.5% CAGR), and the veterinary pain management market is expected to cross $2.20 billion by 2029 (5.91% CAGR), indicating substantial market opportunities.
• The company has an experienced, mission-driven team with business and scientific expertise, including a Scientific Advisory Board with renowned professionals.

Negatives

• The company is a pre-clinical stage pharmaceutical company and has never generated revenue from LPT-CBD product sales in its Pharmaceuticals segment.
• Incurred significant losses since inception, with an accumulated deficit of $36,080,000 as of June 30, 2025.
• The financial statements contain an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• Net loss increased to $544,000 for the six months ended June 30, 2025, from $498,000 in the same period of 2024.
• Revenues decreased by $610,000 to $14,802,000 for the six months ended June 30, 2025, compared to $15,412,000 for the same period in 2024, due to market volatility and trade tariffs.
• The company expects negative cash flows from operations to significantly increase in the foreseeable future due to R&D investments for clinical trials.
• Reliance on third-party manufacturers for drug supplies and commercial scale-up introduces risks of delays, quality issues, and increased costs.
• The company has no sales, distribution, or marketing experience for pharmaceutical products and will need to invest significant resources or rely on third parties for commercialization.

Risks

• The company is a pre-clinical stage company and anticipates significant losses until pharmaceutical products are commercialized.
• May not achieve or maintain sufficient working capital to meet future obligations.
• Expects to need additional funding, which may not be available on acceptable terms, or at all, potentially requiring curtailment, delay, or discontinuation of operations.
• Pharmaceutical product candidates are in preclinical development, and there is no assurance they will receive regulatory approval.
• May not receive, or may be delayed in receiving, necessary approvals for LPT-CBD or future products, affecting business growth.
• If the FDA's Section 505(b)(2) pathway is not available, drug development will likely take significantly longer, cost more, and entail greater complexity and risk.
• Legislative or regulatory reforms in the U.S. or EU may make it more difficult and costly to obtain regulatory clearances or approvals, or to manufacture, market, or distribute products.
• Clinical and preclinical development is uncertain; current pre-clinical programs may experience delays or may never advance to clinical trials.
• Future clinical trials may be delayed, certain programs may never advance, or may be more costly, affecting funding and business.
• Clinical trials may fail to show safety and effectiveness, preventing regulatory approval and commercialization.
• Approved products may fail to achieve market acceptance by physicians, healthcare payers, patients, and the medical community.
• Intense competition and rapid technological change from competitors who may develop similar, more advanced, or more effective therapies.
• Uncertainty regarding third-party payor coverage and reimbursement status of newly approved products.
• Cannabis remains illegal under U.S. federal law, and changes in enforcement priorities could render operations unprofitable or prohibit them.
• The cannabis industry and regulations continue to develop, and adverse changes may impact business.
• Operations in Israel are subject to political, geopolitical, economic, and military conditions, including ongoing conflicts, which could materially and adversely affect the business.
• Difficulty enforcing U.S. judgments against the company, its officers, and directors not in the U.S., or asserting U.S. securities laws claims in Israel.
• The company is governed by Canadian corporate laws, which may have a different effect on shareholders than U.S. corporate laws.
• Business and operations might be adversely affected by security breaches, including cybersecurity incidents.
• Sales or significant short sales of common shares, or the perception of such sales, could depress the market price and impair ability to raise capital.
• As a foreign private issuer and emerging growth company, the company follows certain home country corporate governance practices and reduced disclosure requirements, which may make securities less attractive to investors.

Future Outlook

The company intends to submit an Investigational New Drug (IND) application for its initial Phase 1a study for LPT-CBD approximately one year after LPT-CBD scale-up activities commence (expected three months post-IPO). Phase 1a studies will collect pharmacokinetic and exposure data to form a scientific bridge to Epidiolex for a 505(b)(2) application, estimated to take 6-8 months in parallel with Phase 1a. Phase 1b studies are intended to begin immediately following Phase 1a approval and completion of a repeated-dose GLP safety study. The company also plans to submit an INAD application with the FDA-CVM during the second half of 2025 for veterinary applications. It expects to continue incurring significant losses as R&D expenses increase for clinical trials and additional costs associated with operating as a U.S. public company. The company believes existing capital and IPO proceeds will fund operations through January 2027.

Management Comments

• Management is optimistic about prospects but acknowledges no certainty that anticipated outcomes and sustainable revenue streams will be achieved.
• Management will have broad discretion in the application of the net proceeds from this offering.
• Management believes that existing capital resources and cash flows from operations, together with IPO proceeds, will be adequate to satisfy liquidity requirements through January 2027.

Industry Context

The company operates in the global pain management market, projected to reach $109 billion by 2032, driven by rising chronic diseases and the urgent need for non-opioid alternatives due to the opioid crisis. Its LPT-CBD platform directly addresses this need by offering a sustained-release, non-addictive solution. In the veterinary pain management market, estimated at $1.65 billion in 2024 and growing to $2.20 billion by 2029, increased pet ownership and awareness of pet health needs create significant demand. The beauty and personal care market, projected to reach $693 billion by 2031, also provides a substantial opportunity, particularly with the expansion of e-commerce and rising demand for anti-aging and skincare products. The company's focus on both pharmaceutical innovation and consumer wellness positions it to capitalize on these growing trends, offering diverse solutions in response to pressing health and lifestyle demands.

Comparison to Industry Standards

• LPT-CBD offers a non-addictive pain management solution, a significant differentiator compared to traditional opioid therapies that carry risks of addiction, dependence, and tolerance.
• The proprietary LPT-CBD technology demonstrates high bioavailability (approaching 100% in animal studies when compared to published intravenous CBD data), significantly higher than oral CBD administration (6.5% to 20% bioavailability).
• The sustained-release mechanism of LPT-CBD (up to four weeks from a single injection) provides a potential advantage over daily oral CBD administration, simplifying treatment regimens.
• The FDA's approval of a new class of non-opioid pain medication by Vertex Pharmaceuticals on January 30, 2025, underscores the agency's commitment to non-opioid alternatives, aligning with Innocan's LPT-CBD development.
• Innocan's pursuit of the FDA's 505(b)(2) abbreviated pathway for LPT-CBD leverages existing data from approved drugs like Epidiolex (Jazz Pharmaceuticals), potentially accelerating development compared to a full 505(b)(1) NDA.
• While Epidiolex is covered for 97% of patients with specific epilepsy syndromes, Innocan's LPT-CBD aims for chronic pain management, potentially entering a different, less saturated market segment for CBD-based pharmaceuticals.
• The company's wellness segment, particularly B.I. Sky, has demonstrated market leadership in online marketplaces like Amazon, with a low 0.01% return rate and 87.4% customer return rate within 30 days, indicating strong consumer trust and product efficacy compared to general e-commerce standards.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings.

Related Party Transactions

• On August 3, 2023, Tamar Innovest Limited, a company associated with director Ralph C.L Bossino and the largest shareholder, purchased 17,391 units in a private placement for $179,400.
• On March 7, 2025, Tamar Innovest Limited, the largest shareholder, purchased a debenture unit for gross proceeds of $1,000,000. This debenture is convertible into common shares and includes warrants.
• The debenture and warrants issued to Tamar Innovest Limited are subject to a blocker provision preventing conversion/exercise if it would result in ownership exceeding 19.99% of outstanding common shares.
• The transaction with Tamar Innovest Limited was considered a related party transaction under Canadian securities law, but exempted from valuation and minority approval requirements as it was less than 25% of market capitalization and approved by independent directors.
• Innocan entered into a founders agreement with Brandzon Co Ltd. (co-founded by COO Roni Kamhi) on May 26, 2021, to establish B.I. Sky Global Ltd. Innocan holds 60% and Brandzon holds 40%.
• Innocan extended an owner's loan of approximately $3,000,000 to B.I. Sky, bearing interest and maturing on the earlier of February 15, 2026, or an exit event. No principal or interest payments have been made to date.
• A loan of $14,291 was extended to CEO Iris Bincovich on July 1, 2020, which was non-interest-bearing and fully repaid by December 31, 2023.

Stakeholder Impact

• **Shareholders:** New investors will experience immediate dilution of $9.702 per common share due to the IPO price being substantially in excess of the as-adjusted net tangible book value. Existing shareholders will see an increase in net tangible book value. The IPO and potential Nasdaq listing could increase liquidity and visibility, but the company's going concern warning and pre-clinical stage present high risks.
• **Employees:** The company plans to invest in its people and expand its organization, which could lead to new opportunities. However, the ongoing war in Israel could disrupt operations if employees are called to military service. Equity incentive plans (stock options, RSUs) are in place to attract and retain personnel.
• **Customers:** The company aims to provide safer, effective non-opioid alternatives for chronic pain and innovative self-care/beauty products, potentially improving quality of life and wellness. The Consumer Wellness segment has a loyal and expanding customer base.
• **Suppliers/Partners:** Reliance on third-party manufacturers and CROs means their performance and compliance directly impact the company's development timelines and product quality. Strategic partnerships are crucial for commercialization of pharmaceutical products.
• **Creditors:** The company's accumulated deficit and going concern warning indicate financial risk. The recent convertible debenture issuance adds to liabilities, though the IPO aims to improve liquidity.

Next Steps

• Complete LPT-CBD scale-up activities (expected approximately three months following the completion of this offering).
• Conduct a Good Laboratory Practice (GLP)-compliant single-injection preclinical safety study for LPT-CBD (final reporting anticipated within 6-8 months after scale-up).
• Submit an Investigational New Drug (IND) application for the initial Phase 1a study to the FDA (following safety data availability).
• Commence Phase 1a first-in-human study (30 days post-IND submission, assuming no clinical hold).
• Collect pharmacokinetic (PK) and exposure data of LPT-CBD during Phase 1a studies to form a scientific bridge to Epidiolex for a 505(b)(2) application (estimated 6-8 months, parallel to Phase 1a).
• Begin Phase 1b studies immediately following approval of Phase 1a results and completion of a repeated-dose GLP safety study.
• Submit an INAD application with the FDA-CVM during the second half of 2025 to commence testing LPT-CBD in the U.S. for animal health.
• Engage pharmaceutical companies and industry leaders in licensing discussions for human and animal health applications once key regulatory milestones are achieved for LPT-CBD.
• Continue to expand the Consumer Wellness product portfolio with new developments and releases.
• Expand reach of wellness products to new channels such as retailers.
• Implement new compliance requirements under the Modernization of Cosmetic Regulation Act of 2022 (MoCRA) as FDA regulations are promulgated (proposed rules by Dec 29, 2024; final regulations by Dec 29, 2025).

Key Dates

Recommendation

Innocan Pharma presents a high-risk, high-reward investment opportunity. The Nasdaq IPO is a crucial step to secure funding for its promising LPT-CBD platform, which addresses a significant unmet need in chronic pain management with a non-opioid alternative. The company's strong IP portfolio and FDA's agreement on an accelerated regulatory pathway are positive indicators. However, the company is still in the pre-clinical stage for its primary pharmaceutical product, has a history of net losses, and carries a going concern warning. The recent decline in consumer wellness revenue and geopolitical risks in Israel add to the uncertainty. While the long-term potential is substantial if LPT-CBD successfully navigates clinical trials and regulatory approval, the immediate future involves significant R&D expenditures and inherent risks of drug development. A 'hold' recommendation is appropriate for investors who are already exposed, acknowledging the speculative nature and waiting for clearer clinical and financial milestones before increasing exposure. New investors should approach with extreme caution, given the early stage and financial risks.

Keywords

Pharmaceuticals, Cannabidiol, CBD, LPT-CBD, Drug Delivery, Chronic Pain Management, Non-Opioid, Pre-clinical Development, FDA Approval, 505(b)(2) Pathway, Veterinary Health, Consumer Wellness, Beauty Products, IPO, Nasdaq Listing, SEC Filing, Biotechnology, Medical Devices, Intellectual Property, Israel Operations